|
Enrollment
| | | | | | |
|
Eligibility screening
| |
Telephone
|
x
| | | |
|
Screening assessment
|
MMSE [85]
|
On-site paper
|
x
| |
x
|
x
|
|
Logical Memory [53]
|
On-site paper
|
x
| |
x
|
x
|
|
TMT A [54]
|
On-site paper
|
x
| |
x
|
x
|
|
GDS [56, 86]
|
On-site paper
|
x
| |
x
|
x
|
|
IADL [55]
|
On-site paper
|
x
| |
x
|
x
|
|
Signed informed consent
| |
On-site
|
x
| | | |
|
Allocation/randomization
| | | |
x
| | |
|
Intervention
| | | |
| |
|
Assessments
| | | | | | |
|
Baseline variables
|
|
Demographic information
|
Age, civil status, education
|
On-site paper
| |
x
| | |
|
Family history
|
Dementia, Parkinson disease, and stroke
|
On-site paper
| |
x
| | |
|
Subjective cognitive function
|
ECog-39 [87]
|
On-site paper
| |
x
| | |
|
Lifestyle (lifelong)
|
LEQ [88]
|
At-home paper
| |
x
| | |
|
CAI [89]
|
On-site interview
| |
x
| | |
|
Personality
|
BFI-10 [90]
|
On-site paper
| |
x
| | |
|
SVF-78 [91]
|
On-site paper
| |
x
| | |
|
Hand preference
|
Oldfield Hand Preference [92]
|
On-site paper
| |
x
| | |
|
Premorbid IQ
|
MWT [93]
|
On-site paper
| |
x
| | |
|
Genetic markers
|
APOE ε4 status
|
On-site
| |
x
| | |
|
Cerebral PET (optional consent)
|
Aβ status
|
On-site
| |
x
| | |
|
Primary outcome
|
|
Memory
|
MST [38]
|
On-site Computer
| |
x
|
x
|
x
|
|
Secondary outcomes
|
|
Memory
|
VLMT [94]
|
On-site paper
| |
x
|
x
|
x
|
|
Doors and People [95]
|
On-site paper
| |
x
|
x
|
x
|
|
Executive function
|
Digit Symbol [96]
|
On-site paper
| |
x
|
x
|
x
|
|
TMT B [54]
|
On-site paper
| |
x
|
x
|
x
|
|
Block Tapping [97]
|
On-site paper
| |
x
|
x
|
x
|
|
Stroop [98]
|
On-site paper
| |
x
|
x
|
x
|
|
Attention
|
Digit Span [96]
|
On-site paper
| |
x
|
x
|
x
|
|
TAP [99] subtests: alertness and divided attention
|
On-site Computer
| |
x
|
x
| |
|
Language
|
Semantic/Phonemic Fluency [100]
|
On-site
| |
x
|
x
|
x
|
|
Boston Naming Test [100]
|
On-site paper
| |
x
|
x
|
x
|
|
Lifestyle (current)
|
|
Physical activity
|
FKA [101]
|
At-home paper
| |
x
|
x
|
x
|
|
Cognitive activity
|
CAI Present [89]
|
On-site interview
| |
x
|
x
|
x
|
|
Sleep quality
|
PSQI [102]
|
At-home paper
| |
x
|
x
|
x
|
|
Diet
|
FFQ [33, 63]
|
At-home paper
| |
x
|
x
|
x
|
|
MEDAS [103, 104]
|
On-site paper
| |
x
|
x
|
x
|
|
FFL [19, 62]
|
At-home paper
| |
x
|
x
|
x
|
|
Psycho-affective/worry
|
PSWQ [105, 106]
|
At-home paper
| |
x
|
x
|
x
|
|
RSQ-D [107]
|
On-site paper
| |
x
|
x
|
x
|
|
STAI-G [108]
|
On-site paper
| |
x
|
x
|
x
|
|
Quality of life
|
SF-12 [109]
|
On-site paper
| |
x
|
x
|
x
|
|
WHOQOL-BREF [110]
|
At-home paper
| |
x
|
x
|
x
|
|
Autophagy markers from muscle biopsy (optional consent)
|
LC3 I/II, p62 [72], EP300 [111], proteomics, metabolomics [73]
|
On-site
| |
x
|
x
| |
|
Blood-based markers
|
Polyamine levels [33], metabolomics, proinflammatory biomarkers, and neurotrophin levels
|
On-site
| |
x
|
x
| |
|
Cerebral neuroimaging markers
|
Brain structure, perfusion, function
|
On-site
| |
x
|
x
| |
|
Exploratory outcomes
|
|
Subjective cognitive function
|
ECog-39, adapted [87]
|
On-site paper
| |
x
|
x
|
x
|
|
MMQ, adapted [112]
|
On-site paper
| |
x
|
x
|
x
|
|
Cardiovascular risk factors
|
Blood pressure, lipid profile, glucose metabolism
|
On-site
| |
x
|
x
|
x
|
|
Muscle function/strength*
|
SPPB [113]
|
On-site
| |
x
|
x
|
x
|
|
Handgrip strength
|
On-site
| |
x
|
x
|
x
|
